STOCK TITAN
  1. Home
  2. Sec-filings
  3. VOR
  4. [8-K] Vor Biopharma Inc. Reports Material Event

[8-K] Vor Biopharma Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock VOR logo
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

#4088 Ranked by Market Cap
N/A Ranked by Dividends

VOR Latest News

Oct 3, 2025
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 29, 2025
Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
Sep 23, 2025
Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
Sep 17, 2025
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
Sep 17, 2025
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

VOR Latest SEC Filings

Sep 26, 2025
[SCHEDULE 13G] Vor Biopharma Inc. SEC Filing
Sep 25, 2025
[SCHEDULE 13G] Vor Biopharma Inc. SEC Filing
Sep 15, 2025
[Form 4] Vor Biopharma Inc. Insider Trading Activity
Sep 17, 2025
[8-K] Vor Biopharma Inc. Reports Material Event
Sep 24, 2025
[S-8] Vor Biopharma Inc. Employee Benefit Plan Registration

VOR Stock Data

251.40M
5.19M
39.09%
43.63%
15.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE